Enterprise Innovation | Weill Cornell Medicine

Based in New York City, Weill Cornell Medicine Enterprise Innovation engages and collaborates with Weill Cornell Medicine faculty and trainees while fostering alliances with leaders in the biomedical industry and business and investment community. Our focus is to translate the application of emerging science and new technologies into world-class medical breakthroughs.

Integrating Weill Cornell Medicine’s different teams and resources under a single, united organization, Enterprise Innovation encompasses the entire spectrum of an effective innovation ecosystem. We offer unique opportunities for faculty and trainees to transform their research into medical advances through collaborations including access to the Sanders Tri-Institutional Therapeutics Discovery Institute.

Enterprise Innovation Metrics from FY18 to FY23

520

New Tech Disclosures

183

Issued US Patents

152

Licenses and Options

NewCo Launches

For Inventors and Innovators

Learn about how to collaborate with our team of top-tier business development professionals to bring your innovations to life.

Two men in dark blue suits shaking hands and two women at the table smiling

For Industry, Investors and Partners

Learn about groundbreaking innovations you can partner to fuel a pipeline or launch a new venture.

A Caucasian and an Indian woman holding some booklets and talking

Innovation Ecosystem

Learn more about the infrastructure and different components of Enterprise Innovation.

Four medical students in white coats sitting at a table and listening to a lecture

Programs, Offerings and Support

Explore entrepreneurial programming and education offered by Enterprise Innovation and our ecosystem partners.

Technology Portfolio

Enterprise Innovation brings together the power of industry-leading translational research and clinical care combined with top-tier business development expertise to accelerate innovation to market. Our leading technology portfolio encompasses major pillars of biomedical innovation.

Two doctors and two business reps talking

Collaboration Opportunities

Check out our available research opportunities for potential collaborations.

Events

Jul 29,2024

11:00am to 12:00pm

Bayer's Expert Mondays Webinar: Catching the Attention of VCs,

A woman looking at a computer screen with illustrations of machine parts

Aug 02,2024

9:00am to 5:00pm

Protofacturing Hardware Accelerator

African-American woman wearing white goggles and looking at a circuit board

Aug 07,2024

9:00am to 5:00pm

I-Corps Regional Course hosted by Syracuse University (Deadline:

A Caucasian and an African-American woman looking at a laptop

Aug 13,2024

12:00pm to 12:45pm

NSF I-Corps Virtual Information Session

Testimonials

John P. Leonard, M.D., Senior Associate Dean of Innovation and Initiatives

Getting new innovations across the finish line requires collaboration, often with industry partners, to scale up findings for application in healthcare. Ultimately, we want the work we do here to have a real impact on patients. By fostering an entrepreneurial environment, we can do that.

Lisa Placanica, Ph.D., Senior Managing Director of the Center for Technology Licensing

There’s obviously fantastic research being done at Weill Cornell Medicine. So we want to work with faculty to identify aspects of their research that could be shaped into a product or a service, work with them to develop it and then to forge the partnership with a commercial entity. We also have to have a finger on the pulse of what industry is looking for: what venture firms are investing in, what pharma is trying to fill their pipeline with. And then we make connections between the two. We have to speak the language between the commercial enterprise and the academic researcher.

Randi B. Silver, Ph.D., Associate Dean and Professor of Physiology and Biophysics

Enterprise Innovation has galvanized us to move forward as basic scientists, and to look for translational aspects that could be developed, with an industrial partner, for patient care. As a result, we have been able to get traction in exploring various avenues for commercialization with angel investors, pharma, venture capital and, significantly, our own Tri-Institutional Therapeutics Discovery Institute, none of which would have been possible without support from the Daedalus Fund for Innovation.

Ronald G. Crystal, M.D., Chair of Genetic Medicine and Professor of Medicine

Allying with the right industrial partner is a vital factor in attracting investors, and Enterprise Innovation’s relationships with and access to biopharma and life science leaders make it possible for aspiring scientist/entrepreneurs to find the right match.

News

Lewy-body like inclusion in mutant mouse retina

Preclinical Model Offers New Insights into Parkinson’s Disease Process

July 23, 2024

A new preclinical model offers a unique platform for studying the Parkinson’s disease process and suggests a relatively easy method for detecting the disease in people, according to a study led by Weill Cornell Medicine researchers.

Caucasian man wearing glasses and a white coat in a lab

Prestigious MERIT Grant Funds Research on How the Immune System Can Banish HIV

July 17, 2024

Weill Cornell Medicine has received $4.2 million to study how the immune system in some people infected with HIV can keep the virus under control, which could lead to novel therapeutic strategies for thwarting or eliminating HIV. Dr. Brad Jones, associate professor of immunology in medicine in the Division of Infectious Diseases at Weill Cornell Medicine, was awarded a MERIT grant from the National Institute for Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH).

Translating Research into Next Generation Care Through Collaboration